Literature DB >> 28385809

Free actin impairs macrophage bacterial defenses via scavenger receptor MARCO interaction with reversal by plasma gelsolin.

Christine M Ordija1, Terry Ting-Yu Chiou1,2, Zhiping Yang1, Glen M Deloid1, Melina de Oliveira Valdo1, Zhi Wang1, Alice Bedugnis1, Terry L Noah3, Samuel Jones4, Henry Koziel5, Lester Kobzik6.   

Abstract

Lung injury can release intracellular actin into the alveolar milieu and is also associated with increased susceptibility to secondary infections. We investigated the effect of free (extracellular) actin on lung macrophage host defense functions. Western blot analysis demonstrated free actin release into the lung lavage fluids of mouse models of ozone injury, influenza infection, and secondary pneumococcal pneumonia and in samples from patients following burn and inhalation injury. Using levels comparable with those observed in lung injury, we found that free actin markedly inhibited murine lung macrophage binding and uptake in vitro of S. pneumoniae, S. aureus, and E. coli, (e.g., S. pneumoniae, mean %inhibition, actin vs. vehicle: 85 ± 0.3 (SD); n = 22, P < .001). Similar effects were observed on the ability of primary human macrophages to bind and ingest fluorescent Saureus (~75% inhibition). Plasma gelsolin (pGSN), a protein that functions to bind and cleave actin, restored bacterial binding and uptake by both murine and human macrophages. Scavenger receptor inhibitors reduced binding of fluorescent actin by murine macrophages [fluorescence index (×10-3) after incubation with vehicle, actin, or actin + polyinosinic acid, respectively: 0.8 ± 0.7, 101.7 ± 50.7, or 52.7 ± 16.9; n = 5-6, P < 0.05]. In addition, actin binding was reduced in a MARCO/SR-AI/II-deficient cell line and by normal AMs obtained from MARCO-/- mice. After release from injured cells during lung injury, free actin likely contributes to impaired host defense by blocking scavenger receptor binding of bacteria. This mechanism for increased risk of secondary infections after lung injury or inflammation may represent another target for therapeutic intervention with pGSN.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  actin; alveolar macrophages; plasma gelsolin; scavenger receptors

Mesh:

Substances:

Year:  2017        PMID: 28385809      PMCID: PMC5495953          DOI: 10.1152/ajplung.00067.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  53 in total

1.  Circulating actin-gelsolin complexes following oleic acid-induced lung injury.

Authors:  D B Smith; P A Janmey; S E Lind
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

2.  Macrophages in innate and acquired immunity.

Authors:  Homer L Twigg
Journal:  Semin Respir Crit Care Med       Date:  2004-02       Impact factor: 3.119

3.  Changes in the mesenteric lymph proteome induced by hemorrhagic shock.

Authors:  Anubhav Mittal; Martin Middleditch; Katya Ruggiero; Benjamin Loveday; Brett Delahunt; Mia Jüllig; Garth J S Cooper; John A Windsor; Anthony R J Phillips
Journal:  Shock       Date:  2010-08       Impact factor: 3.454

4.  Evidence of increased Gc:actin complexes in pregnant serum: a possible result of trophoblast embolism.

Authors:  D L Emerson; P Arnaud; R M Galbraith
Journal:  Am J Reprod Immunol       Date:  1983-12       Impact factor: 3.886

5.  Acute ozone-induced change in airway permeability: role of infiltrating leukocytes.

Authors:  S R Kleeberger; B B Hudak
Journal:  J Appl Physiol (1985)       Date:  1992-02

6.  Proteomic analysis of post-hemorrhagic shock mesenteric lymph.

Authors:  Jen-Feng Fang; Lih-Yuann Shih; Kuo-Ching Yuan; Kuan-Ying Fang; Tsann-Long Hwang; Sen-Yung Hsieh
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

7.  Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung.

Authors:  Cherrie-Lee Small; Christopher R Shaler; Sarah McCormick; Mangalakumari Jeyanathan; Daniela Damjanovic; Earl G Brown; Petra Arck; Manel Jordana; Charu Kaushic; Ali A Ashkar; Zhou Xing
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

8.  Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae.

Authors:  Lynnelle A Pittet; Luanne Hall-Stoodley; Melanie R Rutkowski; Allen G Harmsen
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-11       Impact factor: 6.914

9.  Time from illness onset to death, 1918 influenza and pneumococcal pneumonia.

Authors:  Keith P Klugman; Christina Mills Astley; Marc Lipsitch
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

10.  The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles.

Authors:  Mohamed Arredouani; Zhiping Yang; YaoYu Ning; Guozhong Qin; Raija Soininen; Karl Tryggvason; Lester Kobzik
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  13 in total

Review 1.  Lung macrophages: current understanding of their roles in Ozone-induced lung diseases.

Authors:  Sonika Patial; Yogesh Saini
Journal:  Crit Rev Toxicol       Date:  2020-05-27       Impact factor: 5.635

2.  Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia.

Authors:  Zhiping Yang; Alice Bedugnis; Susan Levinson; Mark Dinubile; Thomas Stossel; Quan Lu; Lester Kobzik
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

3.  Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.

Authors:  Mark J DiNubile; Susan L Levinson; Thomas P Stossel; Matthew B Lawrenz; Jonathan M Warawa
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

4.  Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

Authors:  Abla Tannous; Susan L Levinson; James Bolognese; Steven M Opal; Mark J DiNubile
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Authors:  Wesley H Self; Richard G Wunderink; Mark J DiNubile; Thomas P Stossel; Susan L Levinson; Derek J Williams; Evan J Anderson; Anna M Bramley; Seema Jain; Kathryn M Edwards; Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

6.  Plasma gelsolin modulates the production and fate of IL-1β-containing microparticles following high-pressure exposure and decompression.

Authors:  Veena M Bhopale; Deepa Ruhela; Kaighley D Brett; Nathan Z Nugent; Noelle K Fraser; Susan L Levinson; Mark J DiNubile; Stephen R Thom
Journal:  J Appl Physiol (1985)       Date:  2021-03-25

7.  Anti-Fibrotic Activity of an Antimicrobial Peptide in a Drosophila Model.

Authors:  Dilan Khalili; Christina Kalcher; Stefan Baumgartner; Ulrich Theopold
Journal:  J Innate Immun       Date:  2021-05-17       Impact factor: 7.349

8.  Inhibition of inflammatory response in human keratinocytes by magnetic nanoparticles functionalized with PBP10 peptide derived from the PIP2-binding site of human plasma gelsolin.

Authors:  Ewelina Piktel; Urszula Wnorowska; Mateusz Cieśluk; Piotr Deptula; Katarzyna Pogoda; Iwona Misztalewska-Turkowicz; Paulina Paprocka; Katarzyna Niemirowicz-Laskowska; Agnieszka Z Wilczewska; Paul A Janmey; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2019-02-02       Impact factor: 10.435

Review 9.  Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.

Authors:  Ewelina Piktel; Ilya Levental; Bonita Durnaś; Paul A Janmey; Robert Bucki
Journal:  Int J Mol Sci       Date:  2018-08-25       Impact factor: 5.923

10.  Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza.

Authors:  Zhiping Yang; Alice Bedugnis; Susan Levinson; Mark DiNubile; Thomas Stossel; Quan Lu; Lester Kobzik
Journal:  F1000Res       Date:  2019-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.